Literature DB >> 27277008

Perichondrium mesenchymal stem cells inhibit the growth of breast cancer cells via the DKK-1/Wnt/β-catenin signaling pathway.

Min Li1, Hui Cai2, Ya Yang3, Jia Zhang1, Kai Sun4, Yan Yan1, Hangying Qu1, Weiwei Wang5, Jiansheng Wang1, Xiaoyi Duan6.   

Abstract

In recent years, mesenchymal stem cells (MSCs), which possess the ability to specifically home to tumor sites, with the potential of multi-directional differentiation and low immunogenicity, have been reported to inhibit the growth of various types of tumors. In the present study, we isolated MSCs from the rib perichondrium (PMSCs). By comparing PMSCs with bone marrow‑derived mesenchymal stem cells (BMSCs), we demonstrated that PMSCs present biological characteristics similar to those of BMSCs. Furthermore, we explored the effect and antitumor mechanism of PMSCs in rat SHZ-88 breast cancer cells. The growth, migration and invasion of the SHZ-88 cells were significantly inhibited, and the Wnt/β-catenin pathway and its target genes were downregulated in the SHZ-88 cells by PMSC-conditioned medium. The expression level of dickkopf-1 (DKK-1) was higher in the PMSCs than that noted in the SHZ-88 cells. Neutralization of DKK-1 in the PMSC‑conditioned medium attenuated the inhibitory effects of PMSCs on SHZ-88 cells. Therefore, PMSC-secreted DKK-1 is involved in the inhibition of SHZ-88 cell growth, migration and invasion, via the Wnt/β‑catenin signaling pathway. In addition, we demonstrated that PMSCs inhibited the growth of breast cancer in vivo and prolonged the survival time of tumor‑bearing rats. PMSCs inhibited the growth of transplanted breast tumors through the Wnt/β-catenin signaling pathway. In conclusion, our data confirmed that MSCs derived from the perichondrium present biological characteristics similar to those of BMSCs and inhibit the growth of breast cancer cells through the Wnt/β-catenin signaling pathway in vitro and in vivo. DKK-1 secreted by PMSCs played a vital role in controlling the Wnt/β-catenin signaling pathway in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27277008     DOI: 10.3892/or.2016.4853

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

1.  Dickkopf-1 perpetuated synovial fibroblast activation and synovial angiogenesis in rheumatoid arthritis.

Authors:  Li Zheng; Fanlei Hu; Wenjie Bian; Yingni Li; Linqi Zhang; Lianjie Shi; Xiaoxu Ma; Yanying Liu; Xuewu Zhang; Zhanguo Li
Journal:  Clin Rheumatol       Date:  2021-05-19       Impact factor: 2.980

2.  Wenshen Zhuanggu formula effectively suppresses breast cancer bone metastases in a mouse Xenograft model.

Authors:  Jia-Jia Li; Wei-Ling Chen; Jian-Yi Wang; Qian-Wen Hu; Zhen-Ping Sun; Shuai Zhang; Sheng Liu; Xiang-Hui Han
Journal:  Acta Pharmacol Sin       Date:  2017-04-17       Impact factor: 6.150

3.  Value of the level of methylation of RASSF1A and WIF-1 in tissue and serum in neoadjuvant chemotherapeutic assessment for advanced breast cancer.

Authors:  Zhong-Hua Han; Chun-Sen Xu; Hui Han; Chuan Wang; Shun-Guo Lin
Journal:  Oncol Lett       Date:  2017-08-07       Impact factor: 2.967

Review 4.  The Role of Wnt Signal in Glioblastoma Development and Progression: A Possible New Pharmacological Target for the Therapy of This Tumor.

Authors:  Mariachiara Zuccarini; Patricia Giuliani; Sihana Ziberi; Marzia Carluccio; Patrizia Di Iorio; Francesco Caciagli; Renata Ciccarelli
Journal:  Genes (Basel)       Date:  2018-02-17       Impact factor: 4.096

Review 5.  Bidirectional and Opposite Effects of Naïve Mesenchymal Stem Cells on Tumor Growth and Progression.

Authors:  Faramarz Rahmatizadeh; Shiva Gholizadeh-Ghaleh Aziz; Khodadad Khodadadi; Maryam Lale Ataei; Esmaeil Ebrahimie; Jafar Soleimani Rad; Maryam Pashaiasl
Journal:  Adv Pharm Bull       Date:  2019-10-24

Review 6.  Drug Discovery of DKK1 Inhibitors.

Authors:  Hewen Jiang; Zongkang Zhang; Yuanyuan Yu; Hang Yin Chu; Sifan Yu; Shanshan Yao; Ge Zhang; Bao-Ting Zhang
Journal:  Front Pharmacol       Date:  2022-03-09       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.